Home > Pavel Osmančik, ESC 2019 – the PRAGUE-17 Study and Left Atrial Appendage Closure
Atrial Fibrillation

Pavel Osmančik, ESC 2019 – the PRAGUE-17 Study and Left Atrial Appendage Closure

Published Online: September 9th 2019

We spoke to Dr Pavel Osmančik (Department of Arrhythmology, University Hospital Královské Vinohrady, Prague, Czech Republic) about the results from the PRAGUE-17 study and left atrial appendage closure, and the current strategies for preventing cardioembolic events in patients with atrial fibrillation.

Speaker’s Disclosures: Pavel Osmančik has nothing to declare in relation to this video interview.

Questions:
1. What are the current strategies for preventing cardioembolic events in patients with atrial fibrillation? (0:04)
2. The PRAGUE-17 study examined the efficacy of percutaneous left atrial appendage closure compared with novel anticoagulation agents; what are your observations at this point? (0:53)
3. Which patient populations do you consider are most likely to benefit from left atrial appendage closure? (2:47)

touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Filmed in partnership with the Arrhythmia Alliance (A-A) at the European Society of Cardiology (ESC) Congress 2019 in Paris, France, September 2019.

Share this Video
Related Videos In Atrial Fibrillation
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar